Treatment of endocrine tumors by somatostatin analogs;TRAITEMENT DES TUMEURS ENDOCRINES PAR LES ANALOGUES DE LA SOMATOSTATINE

Medecine Therapeutique

Volumn 3, Issue 9, 1997, Pages 749-762

  Chanson, Philippe ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; CARCINOID; CUSHING SYNDROME; DIABETES MELLITUS; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; ENDOCRINE TUMOR; FLUSHING; HUMAN; HYPOPHYSIS ADENOMA; INSULINOMA; NAUSEA; REVIEW; STEATORRHEA; STONE FORMATION; VOMITING; ZOLLINGER ELLISON SYNDROME;

EID: 0030724371     PISSN: 12646520     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Brazeau P., et al. 1973. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179 : 77-79.
2. Bauer W., et al. 1982. SMS 201-995 : a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31 : 1133-1140.
3. Reisine T., Bell G.I. 1995. Molecular biology of somatostatin receptors. Endocr Rev 16 : 427-442.
4. Raulf F., Bruns C., Hoyer D. 1996. Récepteurs de la somatostatine : biologie et pharmacologie moléculaires. In : Epelbaum J., éd. La somatostatine et ses analogues , de la recherche fondamentale à la clinique. Montrouge : John Libbey Eurotext, 11-19.
5. Lamberts S.W.J., van der Lely A.J., de Herder W.W., Hofland L.J. 1996. Octreotide. N Engl J Med 334 : 246-254.
6. Kubota A., et al. 1994. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in the treatment of human endocrine tumors. J Clin Invest 93 : 1321-1325.
7. Vikic-Topic S., Raisch K.P., Kvols L.K., Vuk-Pavlovic S. 1985 Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor and renal cell carcinoma. J Clin Endocrinol Metab 80 : 2974-2979.
8. Miller G.M., et al. 1995. Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 80 : 1386-1392.
9. Chanson P., Timsit J., Harris A.G 1993. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. Clin Pharmacokinet 25 : 375-391.
10. Gillis J.C., Noble S., Goa K.L. 1997. Octreotide long-acting release (LAR) : a review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 53 : 681-699.
11. Sassolas G., Harris A.G., James-Deidier A. and the French SMS 201-995 Acromegaly Study Group. 1990. Long term effects of incremental doses of the somatostatin analog SMS 201-995 in 53 acromegalic patients. J Clin Endocrinol Metab 71 : 391-397.
12. Heron I., et al. 1993. Pharmacokinetics and efficacy of a long acting formulations of the new somatostatin analogue BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab 76 : 721-727.
13. Johnson M.R., Chowdrey H.S., Thomas F., Grint C., Lightman S.L. 1994. Pharmacokinetics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly. Eur J Endocrinol 130 : 229-234.
14. Sassolas G., et al. 1989. Effects of the somatostatin analog BIM 23014 on the secretion of growth hormone, thyrotropin, and digestive peptides in normal men. J Clin Endocrinol Metab 68 : 239-246.
15. Morange I., et al. 1994. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab 79 : 145-151.
16. Marek J., Hana V., Krsek M., Justova M., Caius F., Thomas F. 1994. Long term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. Eur J Endocrinol 131 : 20-26.
17. Giusti M., Gussoni G., Cuttica M., Giordano G., and the Italian Multicenter Slow Release Lanreotide Study Group. 1996. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly : six month report on an Italian multicenter study. J Clin Endocrinol Metab 81 : 2089-2097.
18. Falhbusch R., Honnegger J., Buchfelder M. 1992. Surgical management of acromegaly. Endocrinol Metab Clin North Am 21 : 669-692.
19. Eastman R.C., Gorden P., Glatstein E., Roth J. 1992. Radiation therapy of acromegaly. Endocrinol Metab Clin North Am 21 : 693-712.
20. Vance M.L., Harris A.G. 1991. Long term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Arch Intern Med 151 : 1573-1578.
21. Ezzat S., et al. 1992. Octreotide treatment of acromegaly : a randomized multicenter study. Ann Intern Med 117 : 711-718.
22. Newman C.B., et al. 1995. Safety and efficacy of long-term octreotide therapy in acromegaly : results of a multicenter trial in 103 patients. A clinical research center study. J Clin Endocrinol Metab 80 : 2768-2775.
23. Arosio M., Macchelli S., Rossi C.M., Casati G., Biella O., Faglia G. 1995. Effects of treatment with octreotide in acromegalic patients : a multicenter Italian study. Eur J Endocrinol 133 : 430-439.
24. Warnet A. 1996. Octréotide et tumeurs hypophysaires. In : Epelbaum J., éd. La somatostatine et ses analogues : de la recherche fondamentale à la clinique. Montrouge : John Libbey Eurotext, 45-57.
25. Melmed S., Ho K., Klibanski A., Reichlin S , Thorner M. 1995. Recent advances in pathogenesis, diagnosis and management of acromegaly J Clin Endocrinol Metab 60 : 3395-3402.
26. Chanson P., et al. 1986. Rapid improvement in sleep apnoea of acromegaly after short term treatment with somatostatin analogue SMS 201-995. Lancet i : 1270-1271.
27. Chanson P., et al. 1990. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med 113 : 921-925.
28. Caron P., Cogne M., Gusthiot-Joudet B., Wakim S., Catus F., Bayard F. 1995. Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995). Eur J Endocrinol 132 : 320-325.
29. Al-Maskari M., Gebbie J., Kendall-Taylor P. 1996. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide in acromegaly. Clin Endocrinol 45 : 415-421.
30. Caron P., Morange-Ramos I., Cogne M., Jaquet P. 1997. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 82 : 18-22.
31. Bertherat J., et al. 1993. Somatostatin receptors adenylate cyclase activity and growth hormone (GH) response to octreotide in GH-secreting adenomas. J Clin Endocrinol Metab 77 : 1577-1583.
32. Chanson P., Weintraub B.D., Harris A.G. 1993. Octreotide therapy for thyroid-stimulating-hormone secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med 119 : 236-240.
33. Gancel A , Vuillermet P., Legrand A., Catus F., Thomas F., Kuhn J.M. 1994. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas. Clin Endocrinol 40 : 421-428.
34. Warnet A., et al. 1989. The effect of somatostatin analogue on chiasmal dysfunction from pituitary macroadenomas. J Neurosurg 71 : 687-690.
35. Wajchenberg B.L, et al. 1994. Ectopic adrenocorticotropic hormone syndrome. Endocr Rev 15 : 52-87.
36. Kvols L.K., Martin J.K., Marsh H.M., Moertel G.G. 1985. Rapid reversal of carcinoid crisis with a somatostatin analogue. N Engl J Med 313 : 1229-1230.
37. Kvols L.K., Moertel G.G., O'Connel M.J., Schutt A.J., Rubin J., Hahn R.G. 1986. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 315 : 663-666.
38. Vinik A.I., Maottari A.R. 1989. Jse of somatostatin analog in management of carcinoid syndrome. Dig Dis Sci 34 (suppl. 3) : 14S-27S.
39. Kvols L.K. 1989. Therapy of he malignant carcinoid syndrome. Endocrinol Metab Clin North Am 18 : 557-568.
40. Gorden P. 1989. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 110 : 35-50.
41. Oberg K., Norheim I., Theodorsson E. 1991. Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide. Acta Oncol 300 : 503-507.
42. Saltz L., et al. 1993. Octreotide as an antineoplastic agent in the treatment of functional and non-functional neuroendocrine tumors. Cancer 77 : 244-248.
43. Anthony L., et al. 1993. Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncologica 32 : 217-223.
44. Trautmann M.E., et al. 1993. The role of somatostatin analogs in the treatment of endocrine gastrointestinal tumors. Harm Metab Res 27 : 24-27.
45. Jacobsen M.B., Hanssen L.E. 1995. Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial. J Intern Med 237 : 269-275.
46. Kvols L.K. 1994. Metastatic carcinoid tumors and the malignant carcinoid syndrome. Ann NY Acad Sci 733 : 464-470.
47. Di Bartolomeo M., et al. 1996. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 77 : 402-408.
48. Blanchin M., James-Deidier A., Chaumet-Riffaud P.D , Chayvialle J.A. 1992. Utilisation de l'octréotide dans les tumeurs endocrines digestives Étude française multicentrique. Presse Med 21 : 697-702.
49. Moertel C.G., et al. 1994. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 120 : 302-309
50. Marsh H.M., et al. 1987. Carcinoid crisis during anesthesia : successful treatment with a somatostatin analogue. Anesthesiology 66 : 89-91.
51. Lawrence J.P., Ishizuka J., Haber N., Towsend C.M. Jr, Thompson J.C. 1990. The effect of somatostatin on 5-hydroxytryptamine release from a carcinoid tumor. Surgery 108 : 1131-1135.
52. Sassolas G. 1996. Détection in vivo des récepteurs de la somatostatine par scintigraphie. In : Epelbaum J., éd La somatostatine et ses analogues : de la recherche fondamentale à la clinique. Montrouge : John Libbey Eurotext, 59-67.
53. Nocaudie-Calzada M., Huglo D., Deveaux M , Carnaille B., Proye C., Marchandise X. 1994. Iodine-123-Tyr-3-octreotide uptake in pancreatic endocrine tumors and in carcinoids in relation to hormonal inhibition by octreotide. J Nucl Med 35 : 57-62.
54. 1] octreotide scintigraphy in patients with carcinoid tumours : the predictive value for somatostatin analogue treatment. Eur J Endocrinol 131 : 577-581.
55. Arnold R., et al. 1993. Somatostatin analog and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors. World J Surg 17 : 511-519.
56. Creutzfeldt W., Bartsch H.H., Jacubaschke U., Stöckmann F. 1991. Treatment of gastrointestinal endocrine tumours with interferon-alpha and octreotide. Acta Oncol 30 : 529-535.
57. Tiensuu-Jonson E., Oberg K 1993. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 32 : 225-229.
58. Scherübl H., Wiedenmann B., Riecken E.O., Thomas F., Böhme E., Räth U. 1994. Treatment of the carcinoid syndrom with a depot formulation of the somatostatin analogue lanreotide. Eur J Cancer 30A : 1591-1592 (letter).
59. Maton P.N. 1993. Use of octreotide acetate for control of symptoms in patients with islet cell tumors. World J Surg 17 : 504-510.
60. Verschoor L., Uïtterlinden P., Lamberts S.W.J., Del Pozo E. 1986. On the use of a new somatostatin analogue in the treatment of hypoglycemia in patients with insulinoma Clin Endocrinol 25 : 555-560.
61. Kvols L.K., Buck M., Moertel G.G., 1987. Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995). Ann Intern Med 107 : 162-168.
62. Osei K., O'Dorisio T.M. 1985. Malignant insulinorna . effects of somatostatin analog (compound 201-995) on serum glucose, growth and gastroenteropancreatic hormones. Ann Intern Med 103 : 223-225.
63. Von Eyben F.E., Grodum E., Gjessing H.J., Hagen C , Bech-Nielsen H. 1994. Metabolic remission with octreotide in patients with insulinoma J Intern Med 235 : 245-248.
64. Stehouwer C.D.A., Lems W.F., Fischer H.R.A., Hackeng W.H.L., Naafs M.A.B. 1989. Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide. Acta Endocrinol 121 : 34-40.
65. Wood S.M., Kraenzlin M.E., Adrian T.E., Bloom S.R. 1985. Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue : symptomatic and peptide responses. Gut 26 : 438-444.
66. Vinik A., Llyod R., Cho K. 1990. The use of somatostatin analog in gastroenteropancreatic tumors other than carcinoid. Metabolism 39 (suppl. 2) : 156-162.
67. Mozell E.J., Cramer A., O'Dorisio T.M , Woltering E A. 1992. Long-term efficacy of octreotide in the treatment of Zollinger-Ellison syndrome. Arch Surg 127 : 1019-1026.
68. Rusniewski P., Ramdani A., Cadiot G., Lehy T., Mignon M., Bonfils S. 1993. Long-term treatment with octreotide in patients with the Zollinger-Ellison syndrome. Eur J Clin Invest 23 : 296-301.
69. Scarpignoto C. 1995. Somatostatin analogues in the management of endocrine tumors of the pancreas. In : Mignon M., Jensen R.T., eds. Endocrine tumors of the pancreas. Bale : Karger, 385-414.
70. Kraenzlin M.E., Ch'ng J.L., Wood S.M., Carr D.H., Bloom S.R. 1985. Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology 88 : 185-187.
71. Ch'ng J.L., Anderson J.V., Williams S.J., Carr D.H., Bloom S.R. 1985. Remission of symptoms during long-term treatment of metastatic pancreatic endocrine tumours with long-acting somatostatin analogue. Br Med J 2 : 981-982.
72. Maton P.N., et al. 1985. Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with a pancreatic cholera. N Engl J Med 312 : 17-21.
73. Santangelo W.C., O'Dorisio T.M., Kim J G., Severino G., Krejs G.J. 1985. Pancreatic cholera syndrome : effect of a synthetic somatostatin analog on intestinal water and ion transport. Ann Intern Med 103 : 363-367.
74. Matuchansky C., Rambaud J.C. 1995. VIPomas and endocrine cholera : clinical presentation. diagnosis and advances in management. In : Mignon M., Jensen R.T., eds. Endocrine tumors of the pancreas. Bâle : Karger, 166-182.
75. Boden G., Ryan I.G., Senschmid E.I., Shelmett J., Owen D.E. 1986. Treatment of inoperable glucagonoma syndrome with the long-acting somatostatin analogue SMS 201-995. N Engl J Med 314 : 1686-1689.
76. Souquet J.C., Sassolas G., Forichon J., Champetier P., Partensky C., Chayvialle J.A. 1987. Clinical and hormonal effect of a long-acting somatostatin analogue in pancreatic endocrine tumors and in carcinoid syndrome. Cancer 59 : 1654-1660.
77. Guillausseau P.J., Guillausseau-Scholer C. 1995. Glucagonomas : clinical presentation, diagnosis and advances in management. In : Mignon M., Jensen R.T., eds Endocrine tumors of the pancreas. Bâle: Karger, 183-193.
78. Sassolas G., Chayvialle J.A. 1995. GRFomas, somatostatinomas : clinical presentation, diagnosis and advances in management. In : Mignon M., Jensen R.T , eds. Endocrine tumors of the pancreas. Bâle : Karger, 194-207.
79. Arnold R., Benning R., Neuhaus C., Rolwage M., Trautman M.E. and the German Sandostatin Study Group. 1992 Gastroenteropancreatic endocrine tumors : effects of sandostatin on tumor growth Metabolism 41 (suppl. 2) : 116-118.
80. Liebow C., Reilly C., Serrano M., Schally A.V. 1989. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci USA 86 : 2003-2007.
81. Weltering E.A., et al 1991. Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. J Surg Res 50 : 245-251
82. Trendle M.C., Moertel C.G., Kvols L.K. 1997. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumor. Cancer 79 : 830-834.
83. Koop B.L., Harris A.G., Ezzat S. 1994. Effect of octreotide on glucose tolerance in acromegaly. Eur J Endocrinol 130 : 581-586.
84. Erlinger S., Chanson P., Dumont M., Ponsot P., Warnet A., Harris A.G. 1994. Effect of octreotide on biliary lipid composition and the occurence of cholesterol crystals in patients with acromegaly. A prospective study. Dig Dis Sci 139 : 2384-2388.